Literature DB >> 24677703

Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells.

Hajime Akada1, Saeko Akada, Robert E Hutchison, Kazuhito Sakamoto, Kay-Uwe Wagner, Golam Mohi.   

Abstract

Jak2, a member of the Janus kinase family of nonreceptor protein tyrosine kinases, is activated in response to a variety of cytokines, and functions in survival and proliferation of cells. An activating JAK2V617F mutation has been found in most patients with myeloproliferative neoplasms, and patients treated with Jak2 inhibitors show significant hematopoietic toxicities. However, the role of Jak2 in adult hematopoietic stem cells (HSCs) has not been clearly elucidated. Using a conditional Jak2 knockout allele, we have found that Jak2 deletion results in rapid loss of HSCs/progenitors leading to bone marrow failure and early lethality in adult mice. Jak2 deficiency causes marked impairment in HSC function, and the mutant HSCs are severely defective in reconstituting hematopoiesis in recipient animals. Jak2 deficiency also causes significant apoptosis and loss of quiescence in HSC-enriched LSK (Lin(-)Sca-1(+)c-Kit(+)) cells. Jak2-deficient LSK cells exhibit elevated reactive oxygen species levels and enhanced p38 MAPK activation. Mutant LSK cells also show defective Stat5, Erk, and Akt activation in response to thrombopoietin and stem cell factor. Gene expression analysis reveals significant downregulation of genes related to HSC quiescence and self-renewal in Jak2-deficient LSK cells. These data suggest that Jak2 plays a critical role in the maintenance and function of adult HSCs.
© 2014 AlphaMed Press.

Entities:  

Keywords:  Apoptosis; Conditional knockout; Hematopoietic stem cells; JAK2 kinase; Proliferation; Self-renewal; Signal transduction

Mesh:

Substances:

Year:  2014        PMID: 24677703      PMCID: PMC4063883          DOI: 10.1002/stem.1711

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  41 in total

1.  Cytokines regulating hematopoietic stem cell function.

Authors:  Cheng C Zhang; Harvey F Lodish
Journal:  Curr Opin Hematol       Date:  2008-07       Impact factor: 3.284

2.  AKT1 and AKT2 maintain hematopoietic stem cell function by regulating reactive oxygen species.

Authors:  Marisa M Juntilla; Vineet D Patil; Marco Calamito; Rohan P Joshi; Morris J Birnbaum; Gary A Koretzky
Journal:  Blood       Date:  2010-03-30       Impact factor: 22.113

Review 3.  Myeloproliferative disorders.

Authors:  Ross L Levine; D Gary Gilliland
Journal:  Blood       Date:  2008-09-15       Impact factor: 22.113

4.  Pbx1 regulates self-renewal of long-term hematopoietic stem cells by maintaining their quiescence.

Authors:  Francesca Ficara; Mark J Murphy; Min Lin; Michael L Cleary
Journal:  Cell Stem Cell       Date:  2008-05-08       Impact factor: 24.633

5.  Elucidation of the phenotypic, functional, and molecular topography of a myeloerythroid progenitor cell hierarchy.

Authors:  Cornelis J H Pronk; Derrick J Rossi; Robert Månsson; Joanne L Attema; Gudmundur Logi Norddahl; Charles Kwok Fai Chan; Mikael Sigvardsson; Irving L Weissman; David Bryder
Journal:  Cell Stem Cell       Date:  2007-10-11       Impact factor: 24.633

6.  Foxo3a is essential for maintenance of the hematopoietic stem cell pool.

Authors:  Kana Miyamoto; Kiyomi Y Araki; Kazuhito Naka; Fumio Arai; Keiyo Takubo; Satoshi Yamazaki; Sahoko Matsuoka; Takeshi Miyamoto; Keisuke Ito; Masako Ohmura; Chen Chen; Kentaro Hosokawa; Hiromitsu Nakauchi; Keiko Nakayama; Keiichi I Nakayama; Mine Harada; Noboru Motoyama; Toshio Suda; Atsushi Hirao
Journal:  Cell Stem Cell       Date:  2007-06-07       Impact factor: 24.633

7.  Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.

Authors:  Fabio P S Santos; Hagop M Kantarjian; Nitin Jain; Taghi Manshouri; Deborah A Thomas; Guillermo Garcia-Manero; Debra Kennedy; Zeev Estrov; Jorge Cortes; Srdan Verstovsek
Journal:  Blood       Date:  2009-12-11       Impact factor: 22.113

Review 8.  JNK signaling in apoptosis.

Authors:  D N Dhanasekaran; E P Reddy
Journal:  Oncogene       Date:  2008-10-20       Impact factor: 9.867

9.  Thrombopoietin/MPL signaling regulates hematopoietic stem cell quiescence and interaction with the osteoblastic niche.

Authors:  Hiroki Yoshihara; Fumio Arai; Kentaro Hosokawa; Tetsuya Hagiwara; Keiyo Takubo; Yuka Nakamura; Yumiko Gomei; Hiroko Iwasaki; Sahoko Matsuoka; Kana Miyamoto; Hiroshi Miyazaki; Takao Takahashi; Toshio Suda
Journal:  Cell Stem Cell       Date:  2007-11-20       Impact factor: 24.633

10.  Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis.

Authors:  Animesh Pardanani; Jason R Gotlib; Catriona Jamieson; Jorge E Cortes; Moshe Talpaz; Richard M Stone; Michael H Silverman; D Gary Gilliland; Jolene Shorr; Ayalew Tefferi
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

View more
  41 in total

1.  A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.

Authors:  Mark A Schroeder; H Jean Khoury; Madan Jagasia; Haris Ali; Gary J Schiller; Karl Staser; Jaebok Choi; Leah Gehrs; Michael C Arbushites; Ying Yan; Peter Langmuir; Nithya Srinivas; Michael Pratta; Miguel-Angel Perales; Yi-Bin Chen; Gabrielle Meyers; John F DiPersio
Journal:  Blood Adv       Date:  2020-04-28

Review 2.  Myeloproliferative neoplasm stem cells.

Authors:  Adam J Mead; Ann Mullally
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

3.  Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.

Authors:  Shuo-Chieh Wu; Loretta S Li; Nadja Kopp; Joan Montero; Bjoern Chapuy; Akinori Yoda; Amanda L Christie; Huiyun Liu; Alexandra Christodoulou; Diederik van Bodegom; Jordy van der Zwet; Jacob V Layer; Trevor Tivey; Andrew A Lane; Jeremy A Ryan; Samuel Y Ng; Daniel J DeAngelo; Richard M Stone; David Steensma; Martha Wadleigh; Marian Harris; Emeline Mandon; Nicolas Ebel; Rita Andraos; Vincent Romanet; Arno Dölemeyer; Dario Sterker; Michael Zender; Scott J Rodig; Masato Murakami; Francesco Hofmann; Frank Kuo; Michael J Eck; Lewis B Silverman; Stephen E Sallan; Anthony Letai; Fabienne Baffert; Eric Vangrevelinghe; Thomas Radimerski; Christoph Gaul; David M Weinstock
Journal:  Cancer Cell       Date:  2015-07-13       Impact factor: 31.743

Review 4.  Janus kinases to jakinibs: from basic insights to clinical practice.

Authors:  Massimo Gadina; Mimi T Le; Daniella M Schwartz; Olli Silvennoinen; Shingo Nakayamada; Kunihiro Yamaoka; John J O'Shea
Journal:  Rheumatology (Oxford)       Date:  2019-02-01       Impact factor: 7.580

5.  Stress-induced haematopoietic stem cell proliferation: new roles for p38α and purine metabolism.

Authors:  Victoria A McGuire; J Simon C Arthur
Journal:  Stem Cell Investig       Date:  2016-10-25

6.  Systems-Based Interactome Analysis for Hematopoiesis Effect of Angelicae sinensis Radix: Regulated Network of Cell Proliferation towards Hemopoiesis.

Authors:  Guang Zheng; He Zhang; Yun Yang; Ying-Li Sun; Yan-Jing Zhang; Ju-Ping Chen; Ting Hao; Cheng Lu; Hong-Tao Guo; Ge Zhang; Dan-Ping Fan; Xiao-Juan He; Ai-Ping Lu
Journal:  Chin J Integr Med       Date:  2018-06-25       Impact factor: 1.978

7.  H3K27 Methylation Dynamics during CD4 T Cell Activation: Regulation of JAK/STAT and IL12RB2 Expression by JMJD3.

Authors:  Sarah A LaMere; Ryan C Thompson; Xiangzhi Meng; H Kiyomi Komori; Adam Mark; Daniel R Salomon
Journal:  J Immunol       Date:  2017-09-25       Impact factor: 5.422

Review 8.  JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.

Authors:  Lorraine Springuel; Jean-Christophe Renauld; Laurent Knoops
Journal:  Haematologica       Date:  2015-10       Impact factor: 9.941

Review 9.  Clinical potential of pacritinib in the treatment of myelofibrosis.

Authors:  Ana B Duenas-Perez; Adam J Mead
Journal:  Ther Adv Hematol       Date:  2015-08

Review 10.  The molecular regulation of Janus kinase (JAK) activation.

Authors:  Jeffrey J Babon; Isabelle S Lucet; James M Murphy; Nicos A Nicola; Leila N Varghese
Journal:  Biochem J       Date:  2014-08-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.